Posts by Maxx Chatsko

Navigating Inflation and Interest Rates with Your Hard-Earned Money

Even long-term investors should acknowledge the role that Fed policy is playing in stock valuations.

Oct 22, 2021 - By Maxx Chatsko

Biotechnology

Blue-Sky Thinking in Synthetic Biology

What will it take for synthetic biology to live up to its promise? 7investing Lead Advisor Maxx Chatsko talks with visionary scientist Andrew Hessel about pushing the envelope of living technologies ...

Oct 19, 2021 - By Maxx Chatsko

Biotechnology

Premium Advisor Update

Drug Development is Risky. Let’s Count the Ways.

Oct 14, 2021 - By Maxx Chatsko

Biotechnology

Podcast

7investing Explains: How are Medical Devices and Genetic Tests Regulated?

Health care investors often focus on drug products, but medical devices present unique investing opportunities, too. 7investing Lead Advisors Simon Erickson, Dana Abramovitz, and Maxx Chatsko provide...

Oct 14, 2021 - By Dana Abramovitz

Healthcare Technology

Article

Can Your Gene Editing Stocks Survive the End of Momentum?

There are both opportunities and challenges to modifying DNA for therapeutic applications, but objective information is scarce.

Oct 8, 2021 - By Maxx Chatsko

Biotechnology

Premium Deep Dive

Dicerna Pharmaceuticals Deep Dive: October 2021

Oct 1, 2021 - By Maxx Chatsko

Biotechnology

Video

Maxx’s Top Stock for October 2021

7investing Lead Advisor Maxx Chatsko's Top Stock for October 2021 is one of the most undervalued drug developers on the market.

Oct 1, 2021 - By Maxx Chatsko

Article

Why are $100 Billion Drug Developers Such Lousy Investments?

While 18 companies have crossed that valuation milestone, only one has consistently outperformed the S&P 500 after.

Sep 23, 2021 - By Maxx Chatsko

Biotechnology

Article

Give Your Thesis Time to Breathe, But Be Objective

Knowing when to sell an early-stage drug developer isn't easy, but it's nearly impossible when you're a cheerleader.

Sep 22, 2021 - By Maxx Chatsko

Biotechnology

Article

What’s Next for mRNA?

The therapeutic modality is well-suited to create vaccines for infectious diseases. What about other therapeutic areas?

Sep 15, 2021 - By Maxx Chatsko

Biotechnology

Premium Advisor Update

Annual 2021 Review: Maxx’s 7investing Recommendations

Sep 14, 2021 - By Maxx Chatsko

Biotechnology

Podcast

Bringing Synthetic Biology to Consumers, One Material at a Time

Sustainable materials might be the biggest market opportunity no one is talking about. 7investing Lead Advisor Maxx Chatsko chats with Bolt Threads CEO Dan Widmaier about the opportunities and...

Sep 14, 2021 - By Maxx Chatsko

Biotechnology

Article

The FDA Cracks Down on Safety for Multiple Drug Classes

The moves send a clear signal to drug developers, even if the immediate economic consequences are mostly limited.

Sep 10, 2021 - By Maxx Chatsko

Healthcare Technology

Podcast

7investing Market Focus: Why Are Investors So Optimistic? (8/24/21)

News that the FDA gave Pfizer (NYSE: PFE) full approval for its COVID-19 vaccine, as well as crude prices rallying caused all the major indexes to end the day in the green. Join Maxx Chatsko and...

Sep 2, 2021 - By Maxx Chatsko

Podcast

7investing Market Focus: Why Long-Term Investors Don’t Worry on Red…

If there is one thing investors can predict, it is that there will be volatility in the stock market. Stocks can plummet 20% or more in a single day on no news. While that can be frustrating, it's...

Sep 2, 2021 - By Daniel Kline

General

Premium Deep Dive

Exact Sciences Deep Dive: September 2021

Sep 1, 2021 - By Maxx Chatsko

Healthcare Technology

Video

Maxx’s Top Stock for September 2021

7investing Lead Advisor Maxx Chatsko's top stock to buy in September 2021 is a leading provider of genetic and molecular testing services.

Sep 1, 2021 - By Maxx Chatsko

Healthcare Technology

Article

What Will the Delta Variant Mean for the Stock Market?

Covid cases are up and that spooked some investors, but the effect may be short-lived.

Aug 22, 2021 - By Daniel Kline

General

Article

Repligen Always Seems to Make the Right Moves

The bioprocess leader quietly keeps delivering for shareholders.

Aug 21, 2021 - By Maxx Chatsko

Biotechnology

Article

I Tracked Every Car-Related Expense for 8 Years. Here’s What…

What's the true cost of car ownership? My nerdy habit has provided some interesting answers.

Aug 18, 2021 - By Maxx Chatsko

General

Podcast

7investing Market Focus: The Red Hot Rental Market (8/11/21)

Low interest rates and skyrocketing housing prices have been raising the roof on the rental market. What impact will this have on the overall US economy? 7investing lead advisors Dan Kline and Maxx...

Aug 17, 2021 - By Daniel Kline

Real Estate

Premium Advisor Update

What Defines a Stock Market Bubble?

Aug 13, 2021 - By Maxx Chatsko

Biotechnology

Article

Will We Need a Covid Vaccine Booster Shot?

The companies that make the shot say yes, but the answer is more complicated.

Aug 13, 2021 - By Maxx Chatsko

Healthcare Technology

Podcast

7investing Market Focus: Simon’s Malls Are Returning Back to Normal…

Simon Property Group has disclosed its sales have now fully recovered to their 2019 levels. Post-pandemic, what items are consumers most interested in buying from malls? 7investing lead advisors Dan...

Aug 10, 2021 - By Daniel Kline

Retail

Advisor Update

The 7investing Recommendation That Wasn’t

Maxx explains how red flags prevented him from recommending a seemingly promising biopharma stock to 7investing subscribers.

Aug 9, 2021 - By Maxx Chatsko

Pharmaceuticals

Podcast

The 3 Frameworks for Evaluating Gene Editing Stocks

Most investors have heard about gene editing, but there are many differences between the major technology platforms. 7investing Lead Advisors Maxx Chatsko and Dan Kline introduce three simple...

Aug 3, 2021 - By Daniel Kline

Biotechnology

Podcast

7investing Market Focus: The Fed’s Big Meeting (7/28/21)

Markets have been propped up by low interest rates for quite some time, yet inflation looms on everyone’s mind. What could be the impact for long-term investors? 7investing lead advisors Maxx Chatsko...

Aug 2, 2021 - By Maxx Chatsko

Podcast

7investing Market Focus: China’s Rising Regulations (7/26/21)

China is threatening stricter regulations on its businesses who are listed on American exchanges. What could this mean for long-term investors? 7investing lead advisors Maxx Chatsko and Simon...

Aug 2, 2021 - By Maxx Chatsko

Financial Services

Premium Deep Dive

NeuBase Therapeutics Deep Dive: August 2021

Aug 1, 2021 - By Maxx Chatsko

Biotechnology

Video

Maxx’s Top Stock for August 2021

7investing Lead Advisor Maxx Chatsko's Top Stock for August 2021 is building one of the most versatile technology platforms in genetic medicines. He thinks this under-the-radar stock has the best 10X...

Aug 1, 2021 - By Maxx Chatsko

Article

The Mother of All Binary Events Might End in an…

Deciphera Pharmaceuticals is nearing the most important data readout in its history.

Jul 22, 2021 - By Maxx Chatsko

Biotechnology

Premium Advisor Update

7investing Biotech Recs: The Next De-Risking Events

Jul 15, 2021 - By Maxx Chatsko

Biotechnology

Podcast

How Do You Value Biotech Stocks?

Pre-commercial drug developers don't have traditional fundamentals to analyze, but investors can estimate the likelihood of clinical development. 7investing Lead Advisors Simon Erickson checks in...

Jul 6, 2021 - By Maxx Chatsko

Biotechnology

Premium Deep Dive

Relay Therapeutics Deep Dive: July 2021

Jul 1, 2021 - By Maxx Chatsko

Biotechnology

Video

Maxx’s Top Stock for July 2021

7investing Lead Advisor Maxx Chatsko's Top Stock to buy in July 2021 is incorporating machine learning and artificial intelligence to enable true precision medicine.

Jul 1, 2021 - By Maxx Chatsko

Article

RNAi is Setting a High Bar for Gene Editing

In the second quarter, three different RNAi drug candidates or drug products demonstrated the ability to reverse three different diseases.

Jun 23, 2021 - By Maxx Chatsko

Biotechnology

Article

What Makes a Biotech 10-Bagger?

You don't necessarily have to sift through microcaps. You do need to focus on the right metrics. Maxx Chatsko offers his perspective.

Jun 21, 2021 - By Maxx Chatsko

Biotechnology

Premium Advisor Update

Can Better Antibodies Challenge Cell Therapy?

Jun 14, 2021 - By Maxx Chatsko

Biotechnology

Premium Deep Dive

Invitae Deep Dive: June 2021

Jun 1, 2021 - By Maxx Chatsko

Healthcare Technology

Video

Maxx’s Top Stock for June 2021

7investing Lead Advisor Maxx Chatsko's Top Stock for June 2021 is well positioned to build solutions for some of the biggest obstacles facing the genetic testing markets.

Jun 1, 2021 - By Maxx Chatsko

Healthcare Technology

Article

Thermodynamics and Long-Term Investing

There is a game. You have to play the game.

May 22, 2021 - By Maxx Chatsko

General

Premium Advisor Update

Investing Success Isn’t Measured in Months

May 15, 2021 - By Maxx Chatsko

General

Premium Deep Dive

Xcel Energy Deep Dive: May 2021

May 1, 2021 - By Maxx Chatsko

Energy

Video

Maxx’s Top Stock for May 2021

7investing Lead Advisor Maxx Chatsko's Top Stock for May 2021 is leading the energy transition to zero-carbon power sources and the electrification of transportation.

May 1, 2021 - By Maxx Chatsko

Energy

Article

Can the Bioeconomy Transform Argentina into a Regional Superpower?

Maxx Chatsko notes that while all eyes are on Brazil, the geographic strengths of its southern neighbor cannot be overlooked.

Apr 22, 2021 - By Maxx Chatsko

Biotechnology

Premium Advisor Update

Running with Scissors: Will CRISPR be Humbled in the Clinic?

Apr 13, 2021 - By Maxx Chatsko

Biotechnology

Podcast

AACR Annual Meeting 2021: What’s the Frontier of Cancer Research?

The American Association for Cancer Research (AACR) Annual Meeting 2021 begins this weekend. 7investing Lead Advisors Maxx Chatsko and Dan Kline discuss why the scientific meeting matters to...

Apr 8, 2021 - By Daniel Kline

Biotechnology

Video

Maxx’s Top Stock for April 2021

7investing Lead Advisor Maxx Chatsko's Top Stock to buy in April 2021 is developing a genetic medicine platform with several key advantages over peers.

Apr 1, 2021 - By Maxx Chatsko

Biotechnology